Factor Therapeutics Ltd is conducting a clinical trial in the United States to test a wound healing skin medication for venous leg ulcers, and is seeking participants.
The new treatment, VF001-DP, is a synthetic skin medication that attaches to the base of the ulcer and creates a microscopic scaffold matrix which encourages the body’s skin cells to move into the wound and regrow skin layers
The clinical trial, VF00102, is open to 168 people over the age of 18 with non-healing venous ulcers who meet the eligibility criteria. These include: a small ulcer (approximately the size of a dime) that has been there for more than 6 months; or a larger one that has been there for less than 6 months, explains a media release from the company.
Participants in the trial will have a 2-week screening period, then randomized patients will be treated weekly for 12 weeks, with a 12-week follow-up period.
In addition, qualified participants will receive all trial-related care, as well as financial compensation for time and travel. No insurance is required, the release continues.
For more information about the trial, visit Factor Therapeutics or speak to one’s medical provider.
[Source(s): Factor Therapeutics, PRWeb]
